The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders. Citrin R et al. Expert Rev Hematol. 2016 Jul 22. [Epub ahead of print]. A new era of immune therapy in multiple myeloma. Tai YT et al. Blood. 2016 Jul 21;128(3):318-9. doi: 10.1182/blood-2016-06-719856. The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a “real-world” study: the Royal Marsden…
Spinal disease in myeloma: cohort analysis at a specialist spinal surgery centre indicates benefit of early surgical augmentation or bracing.
Malhotra K et al. BMC Cancer. 2016 Jul 11;16:444. doi: 10.1186/s12885-016-2495-7.
Assessment of Bone Fragility in Patients with Multiple Myeloma Using QCT-Based Finite Element Modelling. Campbell GM et al. J Bone Miner Res. 2016 Jul 25. doi: 10.1002/jbmr.2924. [Epub ahead of print]. Intracranial Involvement by Plasma Cell Neoplasms. Wilberger AC et al. Am J Clin Pathol. 2016 Jul 24. pii: aqw058. [Epub ahead of print]. Upper Gastrointestinal Bleeding Due to Amyloidosis in a Patient…
Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression. Jung SH et al. Ann Hematol. 2016 Jul 1. [Epub ahead of print]. Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma. Jantunen E et al. Expert Rev Hematol. 2016 Jul 15:1-10. [Epub ahead of print]. Peripheral blood stem cells collection…
A study published recently in Nature Communications has identified eight new genetic risk loci for myeloma, providing further insights into the genetic and biological basis of its predisposition. The research, performed at The Institute of Cancer Research (ICR) and part funded by Myeloma UK involved a meta-analysis of pooled data from several independent genome-wide association…
Multiple myeloma: practice patterns across Europe. Raab MS et al. Br J Haematol. 2016 Jun 13. doi: 10.1111/bjh.14193. [Epub ahead of print]. The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable. Prasad V et al. Mayo Clin Proc. 2016 Jun;91(6):707-12. doi: 10.1016/j.mayocp.2016.04.028. Pomalidomide in the management of…
Citrate Extended High Cut-Off Hemodiafiltration for Renal Recovery in Patients With Multiple Myeloma. Marn Pernat A et al. Ther Apher Dial. 2016 Jun;20(3):251-5. doi: 10.1111/1744-9987.12432. Effective Removal of x03BA;-Free Light Chains with Hemodialysis Using Fresenius Ultraflux® EMiC®2 Dialyser in a Patient with Myeloma Cast Nephropathy, with Associated Cost Savings. Jayaballa M et al. Blood Purif. 2016 Jun 8;42(2):158-159. [Epub ahead of print]. Thirteen treatment…
Usual risk factors do not predict venous thromboembolism in newly diagnosed myeloma treated with immunomodulatory drugs. Chalayer E et al. Am J Hematol. 2016 Jun 24. doi: 10.1002/ajh.24454. [Epub ahead of print]. Chronic persistent parvovirus B19 bone marrow infection resulting in transfusion-dependent pure red cell aplasia in multiple myeloma after allogeneic haematopoietic stem cell transplantation and severe graft versus host disease. Karrasch…
Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial. Hulin C et al.J Clin Oncol. 2016 Jun 20. pii: JCO667295. [Epub ahead of print]. A multicenter clinical study to determine the feasible initial dose of lenalidomide for maintenance therapy in patients with multiple myeloma following…
